对卒中治疗的临床试治多集中于梗塞而不是出血。除对原发性蛛网膜下腔出血暂置不论外,梗塞与出血可以区分,这并不是说我们目前能很好地治疗梗塞。可能的理由是,对脑梗塞更易于设想出治疗药物,即使是错误的。药物作用的突出目标是水肿形成,地塞米松是采用的主要药物之一。在蛛网膜下腔出血时,其作用目标是血管痉挛和再出血。在原发性脑内出血时,所有上述目标都可能是影响后果的因素,但对其重要性尚不清楚。 Clinical trials of stroke treatment focus more on infarction than on bleeding. In addition to the provisional temporary subarachnoid hemorrhage temporary regardless of infarction and bleeding can be distinguished, this does not mean that we are currently well treated infarction. The possible reason is that it is easier to think of a cure for cerebral infarction, even if it is wrong. The prominent goal of drug action is the formation of edema, dexamethasone is one of the main drugs used. In subarachnoid hemorrhage, the goal is vasospasm and rebleeding. In primary intracerebral hemorrhage, all of the above mentioned goals can be a contributing factor to the outcome, but its importance is not clear.